source
- Celiac disease faces new therapeutic possibilities as companies target underlying inflammationCeliac disease affects roughly one in every hundred people worldwide, imposing a daily burden that goes far beyond dietary restrictions. Currently, patients have no approved medicines and must rel…
- HMNC Brain Health raises $50M Series B to advance two depression drugsHMNC Brain Health announced it has closed a $50 million Series B financing round. The capital will be used to move two depression drug candidates into mid-stage clinical trials. The round was led…